C-IBLXAmplifier Therapeutics
AMPK activation, metabolic switching
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-IBLX
C-IBLXC-IBLXAMPK activation, metabolic switching
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.7 %���� 30 0 obj > endobj 33 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4��
Life science company Betagenon acquired by American pharmaceuticals company Cambrian Bio About For Clients For Company Owners M&A News Research & Analysis Contact Log In Request Trial Excerpt from our historical coverage March 15, 2023 Life science company Betagenon acquired by American pharmaceuticals company Cambrian Bio Press Release The majority of the shares in Umeå-based life science company Betagenon has been acquired by the American pharmaceuticals company Cambrian Bio from Fort Knox Förvaring. The purchase price is reported to be SEK 270m, but the exact size of the stake is un … tially and do not disclose sources without explicit permission. How do advisors submit transactions for league tables? Advisors may submit completed transactions for league table inclusion by emailing [email protected]. Submissions should include the advisor’s role (e.g. sell-side corporate finance), the target company name and country, and deal value where available. Supporting details can be provided in spreadsheet format. We typically acknowledge submissions within 24
Amplifier Therapeutics 10/17/2023 Capital Raise - Gaebler.com Venture Capital Database Search Menu Get Started Startup Advice Business Ideas Buy a Business Business Plans Form a Legal Entity Startup Resources Freelancing Web Publishing Entrepreneur Interviews Business Demographics Find More Resources Promotion Marketing Advertising Public Relations Find More Resources Sales & Service How to Sell Customer Service Find More Resources Operations Business Strategy Human Resources Leadership Intellectual Property Business Advisors Legal Resources Running a Business Operations Management Busines
Press Release: Cambrian Bio Unveils New Pipeline Company – Amplifier Therapeutics | Erik Schneider LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
Privacy Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Privacy Policy EU Privacy Notice Cookie Policy Social Media policy Privacy Policy March 16, 2023 Introduction Amplifier TX AB and its subsidiaries, Betagenon AB and Betagenon Bio AB (collectively, “ Amplifier, ” “ Company ,”or “ W … vide when you communicate with us, including by providing feedback. It does not apply to information collected: • offline or through any other means, including on any other website operated by any third party (including our affiliates and subsidiaries); or • by any third party (including our affiliates and subsidiaries), including through any application or content that may link to or be accessible from the Website. Please read this Policy carefully to understand our proced … on theWebsite may be served by third-parties, including content providers, and application providers. These third parties may use Cookies alone or in conjunction with other tracking technologies to collect information about you when you use our website. The information they collect may be associated with your personal data or they may collect information, including personal data, about your online activities over time and across different websites and other online services. … , including to respond to any government or regulatory request; • to enforce or apply our terms of use and other agreements; or • if we believe disclosure is necessary or appropriate to protect the rights, property, or safety of Company, our customers, or others. Lawful Basis of Processing; Legitimate Interest, Consent We process your data in connection with our legitimate business interests: including, without limitation, fraud prevention, maintaining the security of our net … ersonal data sales. Residents who wish to exercise this sale opt-out rights may submit a request to [email protected] . However, please know we do not currently sell data triggering that statute's opt-out requirements. California Residents The California Consumer Privacy Act of2018 (CCPA) gives California residents the right to know what
Amplifier Therapeutics investment analysis --> --> Bay Bridge Bio Menu Blog About Biotech DCF tool Contact Amplifier Therapeutics investment analysis October 23, 2023 This is not investment advice. We used AI and automated software tools for most of this research. We did some fact checking but cannot guarantee the accuracy of everything in the article. We do not have a position in or a relationship with the company. Overview Amplifier Therapeutics, a Sweden-based biopharma company, is developing AMPK (AMP-activated protein kinase) activator compounds. These compounds target a spectrum of disea
Betagenon AB - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Betagenon AB Subsidiary Company | Sweden Subsidiary Company | Sweden Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 1 Drugs associated with Betagenon AB ATX-304 Target AMPK Mechanism AMPK agonists Active Org. Amplifier TX AB [+1] Originator Org. Betagenon AB Active Indication Metabolic Diseases [+3] Inactive Indication Diabetes Mellitus, Type 2 Drug Highest … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
%PDF-1.5 %���� 1867 0 obj > endobj xref 1867 41 0000000016 00000 n 0000003088 00000 n 0000003220 00000 n 0000003258 00000 n 0000004853 00000 n 0000005636 00000 n 0000006327 00000 n 0000006986 00000 n 0000007025 00000 n 0000007115 00000 n 0000007230 00000 n 0000008639 00000 n 0000009299 00000 n 0000009412 00000 n 0000010155 00000 n 0000010341 00000 n 0000010961 00000 n 0000011445 00000 n 0000011929 00000 n 0000012306 00000 n 0000012625 00000 n 0000017675 00000 n 0000018052 00000 n 0000018371 00000 n 0000021021 00000 n 0000021409 00000 n 0000021639 00000 n 0000021763 00000 n 0000021912 00000 n 0 … ��}YV�-ަ��x��B��� �m̒�N��(�}H)&�,�#���o0 endstream endobj 1900 0 obj >stream application/pdf bd6b7042-72ad-4929-8e5e-bba779fbfdbc Adobe Illustrator 25.0 (Macintosh) 2021-03-24T11:03:47+01:00 2021-03-24T11:03:47+01:00 2021-03-24T11:03:47+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:65bbfe70-29b7-c444-a738-54117f942f2c uuid:ee263fff-3231-1243-95da-5cadf63378d2 uuid:dc9781cd-820a-2744-ae7f-296f2333d17a xmp.did:66A6819719206811822A897E387FE54C uuid:65E6390686C … c3c5935c9d4 xmp.did:ac9b2e6c-ae66-41f0-acf2-944cfbbe8d15 default converted from application/x-indesign to application/pdf Adobe InDesign 17.4 (Macintosh) / 2023-04-28T09:29:09+02:00 True application/pdf Adobe PDF Library 16.0.7 False endstream endobj 1866 0 obj > endobj xref 0 1867 0000000000 65535 f 0000231719 00000 n 0000233220 00000 n 0000233454 00000 n 0000233590 00000 n 0000233726 00000 n 0000233862 00000 n 0000233998 00000 n 0000234133 00000 n 0000234268 00000 n 0000234 … c3c5935c9d4 xmp.did:ac9b2e6c-ae66-41f0-acf2-944cfbbe8d15 default converted from application/x-indesign to application/pdf Adobe InDesign 17.4 (Macintosh) / 2023-04-28T09:29:09+02:00 True application/pdf Adobe PDF Library 16.0.7 False endstream endobj 1866 0 obj > endobj 1868 0 obj >>> endobj 1908 0 obj > endobj xref 0 1 0000000000 65535 f 1865 2 0003150851 00000 n 0003155597 00000 n 1868 1 0003155783 00000 n 1908 1 0003155976 00000 n trailer ]/Prev 116>> startxref 3156022 %%E
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Press Release: Cambrian Bio Unveils New Pipeline Company – Amplifier Therapeutics | James Hall LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li
CEO.CA | #newsroom back 3 Articles newsroom channel --> --> Get CEO.CA Pro Real-time Level 2 Market Depth Click for live demo Get $50 Off Your First Month! TSX, TSXV or CSE Exchanges Sign up here --> featured articles June 5, 2026 @Joshy CEO Plus is live. First month's on us. June 25, 2026 @newsfile CEO.CA Insights: Exclusive Interviews from THE Mining Investment Event 2026 $AVTGF.US $EQMEF.US $LFLRF.US $LGCXF.US $MAGMF.US $MLMLF.US $PMCCF.US $STTDF.US $VOLMF.US $ALKRY.US $AUMBF.US $DRYGF.US $SALQF.US $WHGOF.US $ALK $AUMB $DRY $EQTY $LG $MGMA $SALT $SCD $STND $SXL $WGO $AGC $LFLR $MLM $PM
Best Anti-Aging Startups – 2025 – Gov Capital Investor Blog Home Crypto Forecast Best Cryptos To Buy Now Bitcoin Forecast Ethereum Forecast BNB Forecast Solana Forecast XRP Forecast Dogecoin Forecast Popular Stocks Best Stocks To Buy Now! Nvidia Stock Forecast Tesla Stock Forecast Amazon Stock Forecast Microsoft Stock Forecast Netflix Stock Forecast Stock Markets USA (US) Stock Forecast Toronto (TSE) Stock Forecast Australian (ASX) Stock Forecast Bombay (BSE) Stock Forecast London (LSE) Stock Forecast FX Forecast Best Currencies To Invest In Now EUR/USD Forecast USD/JPY Forecast GB … l epigenetic reprogramming. This cutting-edge approach is inspired by the Nobel Prize-winning work of Shinya Yamanaka on induced pluripotent stem cells (iPSCs) and further advanced by Altos’s own founding scientist, Juan Carlos Izpisua Belmonte. Belmonte’s research demonstrated that it’s possible to “partially” reprogram cells, rejuvenating them to a state more resilient to stressors without completely erasing their specialized identity and funct … hosla Ventures, and Human Capital, alongside returning backers such as Founders Fund. This financing round reportedly elevated the company’s valuation to $810 million. Prior funding includes a $72. million raise noted in a Pitchbook brief (contextually 2024/early 2025) and an earlier round, possibly a Series A, of $100 million mentioned in other reports. NewLimit was founded in 2022. The strong backing from top-tier venture capital firms underscores confidence in NewLim … nnovative diversified model and its experienced leadership team. The ability to fund multiple “shots on goal” across its portfolio of PipeCos is a distinct advantage in the capital-intensive biotech sector. Traction & Milestones (Recent News 2024-2025): Cambrian Bio and its PipeCos have been making notable progress. Amplifier Therapeutics, a Cambrian affiliate, successfully dosed the first patients in a Phase 1B clinical trial for its AMPK activator, ATX-304, … mbrian Bio was named an Honoree of Fast Company’s Next Big Things in Tech Award. The clinical advancement within its subsidiary companies, such as Amplifier, is a positive indicator of the model’s viability. The continuous launch of new PipeCos demonstrates ongoing execution of their distributed development strategy. Market Opportunit
--> Life Extension News Archive Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immort … novia powers up mitochondrial medicine Longevity Technology - 01-Sep-2025 $350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains Why turtles rarely get cancer Oxford Academic (OUP Academic) - 01-Sep-2025 Research shows turtles’ unique biology helps protect them from tumours despite long lifespans Rapamycin tops NIH review of anti-aging drugs UT Health San Antonio - 28-Aug-2025 Rapamycin extended mouse lifespan by up to 28%, even when given in … onger or weaker, offering new options for healing and repair Aubrai launches to fund longevity science with AI and blockchain CoinDesk - 25-Aug-2025 New DeSci platform uses tokens and AI to speed breakthroughs in ageing research World-first lab breakthrough creates living human skin Interesting Engineering - 22-Aug-2025 New model could transform treatments for burns, wounds, and chronic skin disorders AI-powered proteins unlock faster stem cell breakthroughs OpenAI - 22-Aug-2 … 40 million to support longevity research Longevity Technology - 18-Jul-2025 The fund bridges East-West collaboration and acts quickly using its own capital Brain activity sheds light on why we persist or give up when mentally tired Johns Hopkins Medicine - 17-Jul-2025 Study links two brain areas to cognitive fatigue and motivation during demanding mental tasks Long-term obesity makes young adults biologically older Live Forever Club - 16-Jul-2025 Staying healthy young can kee … diterranean countries age faster than those in northern and western Europe Mito Fund invests in Pretzel Therapeutics for mitochondrial disease therapies Longevity Technology - 15-Jul-2025 New investment fuels development of therapies targeting mtDNA-related energy disorders Iron overload: how aging muscles rust from within UW School of Medicine a
NEW WAYS TO LEAD AND GROW BUSINESS IMPACT IN MEDICAL AFFAIRS by Alloutcoach Brand Logo Log in Sign up EN Alloutcoach By ALLOUTCOACH The mission of @Alloutcoach is to inspire all of us to stretch ourselves and lift others! The show unveils revealing life stories with a global, multicultural perspective on leadership, company culture, mentorship, and the bio-pharmaceutical industry that is deeply-rooted in scientific and sports principles. The conversations you will hear will help you and your organizations transcend differences between people and extend the boundaries of your roles and abilitie … entiveMedicine #AmedeaPharma #Alloutcoach 00:00:00 Highlight 1: Four takeaways: fund research, education, transparency and 00:01:16 Highlight 2: TAME trial explained: endpoints beyond one disease 00:02:05 Highlight 3: “Do something now”: Alzheimer’s screening + vocal diagnostics 00:02:43 Highlight 4: Multi-omics: organ ages, pace of aging, microbiome, proteomics 00:03:54 Highlight 5: Meaning of longevity: purpose, shared responsibility, dignity 00:04:41 Highlight 6: Present L … aging as target” + diagnostics role in preventive care 00:30:36 Call to action: fund TAME + UAE leadership recognition 00:31:05 Steps you can take now: Alzheimer's vocal screening 00:36:05 Where can stakeholders intersect - take action anywhere they live? 00:37:00 How patients, biopharma, regulators, payers align on health span 00:39:12 Is the goal to live forever? Health span vs lifespan 00:39:49 Tithonus myth: why “health span” changes public acceptance 00:41:34 Lifespan vs … e has guided and accelerated with the support of an extraordinary team of Nobel Prize laureates and scientists at Epicrispr. 0:00 - Highlight 1 - Amber's Family's Personal Struggle with Rare Neurodegenerative Disease 1:02 - Highlight 2 - Patient's Real-World Story from the 9/11 tragedy 2:31 - Highlight 3 - Vision & Stamina Needed to Address Unpredictability of Human Biology 4:03 - Speaker Introduction 7:19 - Keys to Transition from R & D to CEO/Commercial Leader 10:22 … am’s Consistency of defending their gold medals at the Paris Olympics. Personal application of mastering cooking pasta professionally to mixing highest quality talent on a team with the right proportion and size of equipment and environment. 33:20 Paris 2024 Olympics Lesson #4 – Never Bypass the Basics to Stay in Competition US Men’s 4 x 100 Spri
Stock Market & Corporate Newsroom | Real-Time Updates | CEO.CA Menu CEO.CA Watchlist Companies News Community SEDAR Research SEDI Insiders Private placements Contests Video Shop What's New? Sign Up Log In Articles # channel Loading... CEO.CA Chairman's Briefing Global Markets. Mining Trends. Every Thursday. Subscribe read first Please read the CEO.CA House Rules before posting. social Youtube Twitter Facebook Linkedin Instagram legal Use of this site indicates acceptance of the Privacy Policy and Terms of Use . The information on this Website is not reliable and not intended to p
Cambrian Bio launches Amplifier Therapeutics to develop clinical-stage AMPK activator Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Vi … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Future Ventures - aVenture Asset Manager Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our dat
News — Mount Nebo Capital 0 Skip to Content Home Strategies About us Portfolio News Contact Open Menu Close Menu Home Strategies About us Portfolio News Contact Open Menu Close Menu Home Strategies About us Portfolio News Contact RECENT NEWS Featured Mount Nebo Capital Welcomes PayPal to Mesh More News Featured August 24, 2025 Mount Nebo Capital Welcomes PayPal to Mesh August 24, 2025 Mesh has successfully closed a landmark funding round of over $130 million , bringing on board an impressive roster of global investors. The round, which included PayPal Ventures … Read more → August … 5, 2023 Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award December 5, 2023 Cambrian Bio, the world’s leading longevity health platform and Mount Nebo Capital’s portfolio company, has been recognized as an honoree of Fast Company’s Next Big Things in Tech Award…. Read more → December 5, 2023 October 17, 2023 Amplifier Therapeutics Doses First Patients in Phase 1b Trial for Cardiometabolic Disease and Secures New Funding October 17, 2023 Amplif … 12/5/23 Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award Cambrian Bio, the world’s leading longevity health platform and Mount Nebo Capital’s portfolio company, has been recognized as an honoree of Fast Company’s Next Big Things in Tech Award…. Read More Cambrian Bio Shelly Morse 10/17/23 Cambrian Bio Shelly Morse 10/17/23 Amplifier Therapeutics Doses First Patients in Phase 1b Trial for Cardiometabolic Disease and Secures New Funding Amplifier Th
RA Capital | Our Portfolio RA Capital menu Home about us About RA Capital Our Team What We Do Social Responsibility News faq venture Venture AT RA Our Portfolio Venture Testimonials techatlas TechAtlas Overview Work With Us map catalog Planetary join us The Right Job RA Capital Raven Our Portfolio Companies knowledge Overview RApport courses Innovator Resources Archives gateway contact contact ra capital investor login Home / Venture / Our Portfolio Our Portfolio Thank you to the innovators who advance human health, each following their unique inspiration and insights, collectively rolling bac
Report: Cambrian Business Breakdown & Founding Story | Contrary Research Companies Reports Foundations & Frontiers Tech Trends Report Conversations About Powered by Discover Companies Reports Foundations & Frontiers Tech Trends Report Conversations Fellowship About Connect Email LinkedIn Twitter Subscribe Powered by © 2026 Contrary Research · All rights reserved Privacy Policy By navigating this website you agree to our privacy policy . Deny Accept Overview Memo Authors 1 Resources 7 Similar Companies 9 Share Cambrian Biotech Cambrian Bio is a biotech company with multiple programs … his collaboration ultimately led to an invitation to establish a new investment fund based in Germany. In 2016, Peyer co-founded Apollo Health Ventures , a fund dedicated to creating and investing in biotech companies developing therapies that target the mechanisms of aging. It was through Apollo that Peyer met Brunemeier. Brunemeier had begun a joint Ph.D. program at Scripps and Oxford studying the biochemistry of aging before leaving academia to launch new companies full-ti … stant depression. With a personal interest in slowing aging, Angermayer and his fund, Apeiron Investment Group , would go on to provide the financial foundation for Cambrian’s launch, anchoring the company’s $60 million raise as it emerged from stealth in 2021. As Cambrian expanded, James invited Juliette Han to join Cambrian as COO and CFO in 2020 . Han was a former mentor to James at McKinsey and before Cambrian, she was Chief of Staff at Two Sigma Investments, COO of peopl … 00 million in October 2021. The financing was co-led by Anthos Capital and SALT Fund, with existing investors such as Apeiron Investment Group (co-founder, Angermeyer’s fund), Future Ventures, and Moore Capital also investing in the round. Several of Cambrian’s portfolio companies have raised capital as well. As of November 2025, Amplifier Therapeutics has raised a total of $33.3 million , all of which came from its Series A round led by Future Ventures and RA Capital Managem … onomists at MIT proposed that biotech productivity could improve when companies apply principles of portfolio theory. They suggested that isolating scientific bets into independent entities reduces correlated risk and creates the opportunity to raise program-level debt. This is a feature that has enabled Bridge Bio to achieve three FDA approvals
News — Future Ventures Home Team News Investments Jobs Connect Home Team News Investments Jobs Connect OUR STORIES Recent talks, blog posts, media, and links from the Future Ventures team and our Portfolio Companies Portfolio companies listed on time’s top greentech companies of 2024 CONGRATS to our portfolio companies: Beeflow, Better Meat, Commonwealth Fusion and Verdant Robotics. They were listed among America’s top green tech companies in 2024, showcasing innovative solutions for a sustainable future, Read more in the link below Learn more Steve jurvetson … ilot Customers We’re delighted to share our first investment in Future Ventures Fund 3. The founders, Anthony Jules and Rodney Brooks, both world experts in robotics, have gone back to their roots, building robots that will be transformative for people. Learn more Future Ventures Partner Maryanna Saenko featured on bios ventures podcast Hear from Maryanna Saenko about her experiences and current work at Future Ventures. Hosted by the BIOS community of Life Scien … aenko joins Future of Life podcast to discuss how venture capital works, how to fund innovation, and what the fields of investing and philanthropy could learn from each other. Click below for the full podcast. Learn more future ventures closes its Third fund Future Ventures is proud to announce the closing of Future Ventures Fund III, at the same $200M size as our prior two funds. We are excited to help the next generation of hard-tech companies forge a better f … Series A round here! Learn more future ventures closes its second fund Future Ventures 2 is our second $200 million fund, closed almost two years after launching our flagship fund. For the past two years, we sourced and invested in companies whose mission is to change the world for the better. We have no intention to veer from that course, and are humbled by the support from our limited partners. Read more in the link below. Learn more Future Ventu … Future Ventures Officially Launches Hello Future. Future Ventures Fund 1 is our flagship $200 million venture fund focused on seed and early-stage investments in trailblazing, purpose-driven entrepreneurs with ideas that have the potential to reinvent entire industries. We were thrilled to have the support of a dream team of l
ATX-304(ATX-304) - 药物靶点：AMPK_在研适应症：心血管疾病，代谢综合征，肥胖_专利_临床_研发 产品 数据 资源 版本对比 预约演示 免费注册 更新于：2026-06-05 ATX-304 更新于：2026-06-05 概要 研发状态 临床结果 转化医学 药物交易 核心专利 临床分析 批准 特殊审评 概要 基本信息 药物类型 小分子化药 别名 ATX-304、 O 304、 O-304X + [1] 靶点 AMPK 作用方式 激动剂 作用机制 AMPK激动剂(AMP活化蛋白激酶激动剂) 治疗领域 心血管疾病 内分泌与代谢疾病 在研适应症 心血管疾病 代谢综合征 肥胖 + [1] 非在研适应症 2型糖尿病 原研机构 Betagenon Sweden AB 在研机构 Betagenon Sweden AB Amplifier TX AB Cambrian BioPharma, Inc. 非在研机构 - 权益机构 - 最高研发阶段 临床2期 首次获批日期 - 最高研发阶段(中国) - 特殊审评 - 登录后查看时间轴 结构/序列 分子式 C16H11Cl2N3O2S InChIKey WEDWLYRQKUTOAX-UHFFFAOYSA-N CAS号 1261289-04-6 关联 2 项与 ATX-304 相关的临床试验 CTIS2024-514744-91-00 /
Programs Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close This is a headline on two lines that describes the page Amplifier™ is developing ATX-304, a pan-AMPK and mitochondrial activator in clinical development for cardiometabolic diseases Candidate IND-enabling Phase I Phase II Phase I
Contact Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Get in touch with us We want to hear from you with your questions about Amplifier. We invite you to contact us with your thoughts and ideas, or if you are interested in working for or investing in Amplifier as we build our company … een received! Oops! Something went wrong while submitting the form. By clicking submit, you are agreeing to our privacy policy. About Us Science Programs Contact News & Publications Policies Copyright © 2023 Amplifier TX AB. All rights reserved.
JPM Week Events – RESI Conference Skip to content Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program Guides Photo Albums Registration RESI San Diego (June) RESI Boston (Sept) Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program … 11th Floor Annex 995 Market Street, San Francisco Source LaunchBio and Inspira Fund Innovators Social Hour @ JPM 16:00 – 19:00 7 Social, San Francisco, CA Source Sidley and Innovation Endeavors Happy Hour Reception @JPM 2026 16:00 – 18:30 Barbarossa Lounge | 714 Montgomery St., San Francisco, CA 94111 Sign Up Source Berkeley Bio Startup Showcase @ JPM 16:00 – 18:00 San Francisco, CA, USA Source Start Up Health APOLLO HOUSE – The Founders & Founder … 00 – 20:30 San Francisco, CA, USA Source AI Health Happy Hour with Fusion Fund & AIX 18:00 – 21:00 AIX Ventures, 334 Brannan St., San Francisco, CA 94107 Source Venture University × TopContenders JPM Week Deep Tech Investor Session Biotech · Pharma · Healthcare · AI-Enabled Deep Tech 18:00 – 21:00 San Francisco, CA, USA Source Bits in Bio Reception @ JPM / SF Healthcare Week 18:00 – 20:30 Sign Up The Future of Women’s Health: Investment Trends and … Cocktail Reception at JPM Minna Gallery, 111 Minna St. San Francisco, CA Source Grant Engine @ JPM 2026 – Mastering the Funding Landscape in a Complex Capital Market Metropolitan Club, 640 Sutter St, San Francisco, CA 94102 Sign Up Source Fireside chats with Hogan Lovells during JPM 2026 – Women’s Breakfast: Trailblazers in Life Sciences San Francisco, CA, USA Sign Up Source Fierce JPM week 5 Embarcadero Center, Hyatt Regency, San Francisco, CA Sign Up Source Elicit AI
Copy of Amplifier Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Amplifier Therapeutics to Present Preclinical Data of ATX-304 in Combination With Semaglutide at ENDO 2025 3min to read July 11, 2025 New York – July 11, 2025 – Amplifier Therapeutics, a Cambrian Bio pipeline company, to
Press & Publications Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close News & Press See media contact View Publications No items found. July 11, 2025 3min to read Amplifier Therapeutics to Present Preclinical Data of ATX-304 in Combination With Semaglutide at ENDO 2025 Amplifier
Programs Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close This is a headline on two lines that describes the page Amplifier™ is developing ATX-304, a pan-AMPK and mitochondrial activator in clinical development for cardiometabolic diseases Candidate IND-enabling Phase I Phase II Phase I
New Science Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close AMPK and mitochondria are key regulators of cellular metabolism AMPK and mitochondria work together to maintain cellular energy balance. AMPK senses when energy levels are low and brings additional sugar and fat into the cell.
Home Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Harnessing the potential of AMPK activation to address metabolic disease Explore ATX-304 Harnessing the potential of AMPK activation to address metabolic disease Explore ATX-304 Featured Publications AMPK activator ATX-304 reduces ox
Cambrian Bio About Science Pipeline Team Careers News & Publications Blogs Contact Back Copied! Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management 5 mins to read October 17, 2023 Author: Cambrian Bio NEW YORK, October 17, 2023 – Amplifier Therapeutics, a Cambrian Bio pipeline company, today announced the dosing of the first patient in the company’s Phase 1B clinical trial investigating ATX-304, a peripherally restricted pan-AMPK activator being developed for the tre
Amplifier TX AB - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 19 Feb 2026 Amplifier TX AB Holding Company | 2001 | New York, United States | 10-50 | www.amplifier-tx.com Holding Company | 2001 | New York, United States | 10-50 | www.amplifier-tx.com Last update 19 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Cardiovascular Diseases Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse into the focused therapeu … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Copy of Amplifier Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Press Release: Cambrian Bio Unveils New Pipeline Company – Amplifier Therapeutics 5min read March 14, 2023 New York, New York, March 14, 2023 - Cambrian Bio , a clinical-stage biotechnology company focused on treating an
Betagenon AB - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Betagenon AB Subsidiary Company | Sweden Subsidiary Company | Sweden Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 1 Drugs associated with Betagenon AB ATX-304 Target AMPK Mechanism AMPK agonists Active Org. Amplifier TX AB [+1] Originator Org. Betagenon AB Active Indication Metabolic Diseases [+3] Inactive Indication Diabetes Mellitus, Type 2 Drug Highest … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Press & Publications Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close News & Press See media contact View Publications No items found. July 11, 2025 3min to read Amplifier Therapeutics to Present Preclinical Data of ATX-304 in Combination With Semaglutide at ENDO 2025 Amplifier
Cracking the Methuselah code - Rational Optimist Society Subscribe Sign in Cracking the Methuselah code The quest to cure aging Rational Optimist Society Dec 07, 2025 57 17 8 Share By David Galland Pretty much since the dawn of recorded history, humans have been fascinated by the idea of living far beyond normal lifespans. The authors of the Bible tell us that Adam (the original) lived 920 years but was outdone by Methuselah—the grandfather of Noah—who was said to have lived 969 years. John Appel For reasons lost to the cosmos, over my career I have become acquainted with a cadre of individual … r, at the age of 14 Laura was accepted into MIT and later founded The Longevity Fund with Peter Thiel. To this day I continue to work with John Mauldin who, along with Dr. Mike Roizen of the Cleveland Clinic, author of The Great Age Reboot , regularly publishes research on aging. And I am pleased to count as a friend and collaborator Chris Wood, Senior Editor of Transformative Age , a research publication dedicated to tracking the latest in life extension technologies. Chris … a new wave of interest in regenerative medicine. His research won him the Nobel Prize in Physiology or Medicine in 2012. Yamanaka’s process involves infusing a harmless virus with four special proteins (Oct4, Sox2, Klf4 and c-Myc) that are collectively referred to as either OSKM or the Yamanaka Factors. The virus with the Yamanaka Factors is able to enter the targeted cells, activating them to “reset” to pluripotent stem cells. While near miraculous, there are “complications” … scientists from universities and research institutions worldwide are invited to submit proposals for interventions to be tested. What makes the ITP unique is that the studies are conducted simultaneously at three independent laboratories: The Jackson Laboratory (Maine), the University of Michigan and the University of Texas Health Science Center at San Antonio. This replication across sites eliminates many sources of bias and ensures reproducibility. Dozens of interventions h … ventually — cure aging itself. With adequate funding and the steadily advancing application of AI across the sciences, we will see regular breakthroughs going forward. Just as improved sanitation and the invention of specialized drugs and antibiotics eliminated a wide array of causes of death in the past… epigenetic reprogramming, CRISPR, and a h
American Society of Nephrology | Kidney Week - Abstract Details (2023) ASN's Mission To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world. learn more Contact ASN 1401 H St, NW, Ste 900, Washington, DC 20005 [email protected] 202-640-4660 The Latest on X @ASNKidney Excellence in Patient Care Kidney Health Initiative KidneyX Donate Communities My ASN Login Education Live Events Kidney Wee … act Policy Team Grants KidneyCure Transition to Independence Clinician Educator Grant Research Fellowships Travel Support Faculty Development Award NIH Grants and Funding Additional Grants and Funding Membership Join/Renew Become a Member Renew Your Membership Member Benefits Summary Member Benefits Guide About Membership Membership Categories Membership Numbers Member Map Fellow of the ASN (FASN) Services Publications Discount ASN Compensation Tool Download Membership Card M … tment of Health and Human Services (HHS) has announced the 2026 KidneyX EMPOWER Prize Challenge, a $4 million national... read more Wednesday, March 18, 2026 @ 2:00 PM ASN Health Policy Scholar Suzanne Watnick, MD, FASN testified before the Health Subcommittee of the House Committee on Ways and Mean... read more Research and Innovation Funding Transforming Dialysis Safety Catalyze Innovation and Treatment Innovation Accelerator Connect With ASN Contact Translate Sitemap Terms
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
11 anti-aging biotech companies leading longevity in 2026 Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by s … nown as “Yamanaka factors”, named after Japanese stem cell researcher and Nobel Prize laureate Shinya Yamanaka – that can transform somatic cells into pluripotent stem cells, inducing changes in gene expression and cellular behavior. This effectively reverses or modifies the epigenetic markers associated with aging, rejuvenating cells and tissues, and potentially slowing down or reversing the effects of aging and age-related diseases (such as neurodegenerative conditions).&nb … formative medicines. Altos’ immediate focus when it launched was to fund its scientists and researchers to properly understand rejuvenation, such as how to tailor reprogramming to see if it can rejuvenate animals without killing them, and whether the process can be carried out using ordinary drugs instead of through genetic engineering. For a while after its launch, not much was known about the company’s activities. But, finally, in 2024, a paper was publish … onal strategy, combining the advantages of a biotech company, a venture capital fund, and an incubator. Since its inception, it has developed a pipeline of companies and therapies that can treat and prevent age-related diseases and lengthen healthspan. The anti-aging company believes that the future of medicine lies in approaching these diseases proactively, removing damage at a cellular level before a person becomes a patient. Each candidate in CambrianR … ($4.3 million) in financial support from the Wallonia region of Belgium to help fund the development costs of GF-1002 for the treatment of metabolic-associated steatohepatitis (MASH). More recently, the company raised £800,000 ($1.06 million) through a share subscription intended to advance its scientific programmes and strengthen its negotiating
Cambrian Bio’s Drug Strategy for Age-Related Diseases Contact us News & Insights Cure Innovation Index Healthcare News Investment Founder Stories Cure Original Reports Cure Conversations Racing to Cures: The Cure U.S.-China Biotech Competitiveness Scorecard June 22, 2026 What Makes an Institution Innovative? A Cure Original Report April 29, 2026 Apply for Membership Work in NYC Join Now Cure Residents People of Cure Your Home in NYC Members can access hotdesking, private conference rooms, event space, a cafe, and a gym—all within a healthcare focused environment. Learn More Learn More Atte … drug that can head off diseases of aging and extend healthy lifespans. Now the prize is tantalizingly close, with accelerating advances in the basic biology of aging and the underlying causes of cancer, Alzheimer’s disease, cardiovascular disease and other conditions common with advancing age. Yet translating these discoveries to drug development still have hurdles to pass. James Peyer, PhD, CEO and Founder of Cambrian Bio, talked about his company’s strategy for pursuing tr … mely hard,” Peyer stated. Why aren’t pharma or venture capitalists clamoring to fund such drug development? One issue is that aging isn’t a disease. There’s nothing to cure. In the eyes of the FDA, aging is not an indication that merits treatment. Peyer’s answer to that problem is to instead think of longevity drugs as multi-disease preventatives. “With the FDA we already have a regulatory system for approving prevention drugs,” said Peyer. “That’s what a longevity drug would … Mission Our Team Newsroom Partnerships and Sponsorships Get in touch Contact us Apply for Membership Newsletter Sign Up Privacy Privacy Policy Terms of Use © 2026 Cure Experience Services, LLC. All Rights Reserved.
Amplifier TX AB (Amplifier TX AB) - 药物管线_专利_临床试验_投融营收_最新药物:ATX-304 产品 数据 资源 版本对比 预约演示 免费注册 更新于：2026-02-19 Amplifier TX AB 控股公司 | 2001 | New York, United States | 10-50 | www.amplifier-tx.com 控股公司 | 2001 | New York, United States | 10-50 | www.amplifier-tx.com 更新于：2026-02-19 概览 管线布局 药物交易 转化医学 营收 科研基金(NIH) 投资 融资 概览 标签 心血管疾病 内分泌与代谢疾病 小分子化药 疾病领域得分 一眼洞穿机构专注的疾病领域 暂无数据 技术平台 公司药物应用最多的技术 暂无数据 靶点 公司最常开发的靶点 暂无数据 疾病领域 数量 内分泌与代谢疾病 1 排名前五的药物类型 数量 小分子化药 1 排名前五的靶点 数量 AMPK(AMP活化蛋白激酶) 1 关联 1 项与 Amplifier TX AB 相关的药物 ATX-304 靶点 AMPK 作用机制 AMPK激动剂 在研机构 Cambrian BioPharma, Inc. [+1] 原研机构 Betagenon Sweden AB 在研适应症 心
Amplifier Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Amplifier Therapeutics Website: Amplifier Therapeutics Business Area(s) Protein Kinase Description Developing AMP-activated protein kinase activator compounds. Company Location(s) 228 Park Ave S New York , NY 10003 United States body Sign up for news Contact Us Add an Employer About the
Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Comp … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Searc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management October 17, 2023 | 4 min read Twitter LinkedIn Facebook Email Print Amplifier Therapeutics, a Cambrian Bio p … sp; 2 min read · Gabrielle Masson Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Senior Director of Clinical Development at Cambrian Bio - Mozibox Ask Mo Jobs Career Studio Resumes Mock Interviews Salaries 1:1 Coaching Voices of Physicians Hire physicians Log in Sign up guest-signup#show" data-guest-signup-action-param="apply" data-guest-signup-job-id-param="244971" data-guest-signup-job-title-param="Senior Director of Clinical Development" data-guest-signup-job-company-param="Cambrian Bio" data-guest-signup-job-url-param="/jobs/244971/job_link_redirect?click_source=job_detail&guest_token=eyJqb2JfaWQiOjI0NDk3MSwiZXhwIjoxNzgyMzgyNTcyfQ%3D%3D--dd98c2dc4a027560046d9668f17 … Dk3MSwiZXhwIjoxNzgyMzgyNTcyfQ%3D%3D--dd98c2dc4a027560046d9668f17be12fc4a6f5b1"> Apply guest-signup#show" data-guest-signup-action-param="apply" data-guest-signup-job-id-param="244971" data-guest-signup-job-title-param="Senior Director of Clinical Development" data-guest-signup-job-company-param="Cambrian Bio" data-guest-signup-job-url-param="/jobs/244971/job_link_redirect?click_source=job_detail&guest_token=eyJqb2JfaWQiOjI0NDk3MSwiZXhwIjoxNzgyMzgyNTcyfQ%3D%3D--dd98c2dc4a0 … ack of your job search Save personal notes for each job to track your thoughts, application status, and follow-ups. Try for free Upload your resume Sign up to upload your resume and get AI-powered customization for job applications. Sign up free Practice your interview Get AI-powered mock interviews tailored to this Senior Director of Clinical Development role. Upload your resume and practice with real-time voice feedback. Sign up to practice Ask Mo • Senior Director of Clini … red authentication-modal#close" aria-label="Close"> Please sign up or log in to apply to this opportunity. Log in Sign up Join Mozibox Get physician jobs matched to you Create an account to continue applying and see more relevant roles. Current job Continue with Google OR Already have an account? Log in ga#track" data-ga-event-value="click_not_physician_continue" data-ga-category-value="Signup" data-ga-source-value="guest_signup_modal"> Not a physician? Continue to external s … onChange"> Job is no longer available report-job-modal#handleReasonChange"> Job apply link is broken report-job-modal#handleReasonChange"> Job is not for physicians report-job-modal#handleReasonChange"> Job is a duplicate report-job-modal#handleReasonChange"> Job is a scam or fake report-job-modal#handleReasonChange"> Job has incorrect informatio
Jobs at Cambrian Biopharma | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
Head of Legal @ Cambrian Biopharma | Future Ventures Job Board Home Team News Investments Connect Home Team News Investments Jobs Connect Be the Future. Future Ventures is more than a name for us. We invest in companies that emphasize sustainability, innovation, and inclusive culture. Join us in our mission to make an impact on future generations. companies Jobs Search jobs Explore companies Join talent network Talent My job alerts Head of Legal Cambrian Biopharma This job is no longer accepting applications See open jobs at Cambrian Biopharma . See open jobs similar to " Head of Legal &q
Copy of Amplifier Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management 5min read October 17, 2023 NEW YORK, Octobe
Amplifier doses first patients in trial and closes new financing Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Next Health opens flagship .
News and Publications About Science Pipeline Team Careers News & Publications Blogs Contact News & Publications Cambrian Bio Presents Positive Human Translational Data for ATX-304, the First AMPK Network Activator, at the American Diabetes Association's 86th Scientific Sessions 10 mins to read 18 June 26 Cambrian Bio Presents Positive Human Translational Data for ATX-304, the First AMPK Network Activator, at the American Diabetes Association's 86th Scientific Sessions 18 June 26 10 mins to read min read Cambrian Bio to Present Two Posters on ATX-304 at the American Diabetes A … 23 Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award Cambrian Bio named an honoree of Fast Company's Next Big Things in Tech Award. The purpose of the award is to celebrate technological breakthroughs that are changing the way we live. See More Visit 5 mins to read 17 October 23 Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capi … — and industry — are seeking to extend healthy lives.” As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked. Cambrian BioPharma CEO James Peyer weighs in on the TAME trial. Visit Endpoints News 20 May 22 A new spinout wades into ovarian aging, armed with a seed round and experimental drugs from Mass General Oviva Therapeutics, a pipeline company of New York-based Cambrian Biopharma, emerged from stealth to dive into the idea of extending w … oresight Institute Biotech & Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors” In this session, James Peyer, PhD, CEO of Cambrian BioPharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starti … ing the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics. Visit Longevity Technology 11 February 21 Longevity.Technology: International Day of Women and Girls in Science In 2015, The UN declared February 11th the “Internat
Cambrian Bio launches Amplifier Therapeutics Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sector Approac
Cambrian Bio Launches Amplifier Therapeutics | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay informed! Subsc
Amplifier Launches to Bring First AMPK Activator to the Clinic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Amplifier Launches to Bring First AMPK Activator to the Clinic March 14, 2023 | 2 min read | Kate Goodwin Twitter LinkedIn Facebook Email Print Pictured: Financing concept/Getty Images Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Home Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Harnessing the potential of AMPK activation to address metabolic disease Explore ATX-304 Harnessing the potential of AMPK activation to address metabolic disease Explore ATX-304 Featured Publications AMPK activator ATX-304 reduces ox
Press Release: Cambrian Bio Unveils New Pipeline Company – Amplifier Therapeutics | James Peyer, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Cambrian Bio About Science Pipeline Team Careers News & Publications Blogs Contact Back Copied! Cambrian Bio Unveils New Pipeline Company – Amplifier Therapeutics 5 mins to read March 14, 2023 Author: Cambrian Bio New York, New York, March 14, 2023 - Cambrian Bio , a clinical-stage biotechnology company focused on treating and preventing chronic diseases of aging, today announced the launch of its new pipeline company, Amplifier Therapeutics . The organization will develop ATX-304, a pan-AMPK (AMP-activated protein kinase) activator. Amplifier has acquired Betagenon AB, a Swedish biopharma
About Us Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical trial and closes new financing from Future Ventures and RA Capital Management About Us Science Programs News & Publications Amplifier Therapeutics is a Bio PipeCo Copyright © 2023 Amplifier Therapeutics. All rights reserved. Policies Press Contact Menu Close Amplifier Therapeutics™ is run by an accomplished team with deep and proven experience in clinical development and small molecule AMPK activators Board of Directors James Peyer, PhD Executive Chair CEO Cambrian Bio Read full bio